venetoclax (Venclexta)
Jump to navigation
Jump to search
Indications
- treatment of patients with chronic lymphocytic leukemia (CLL) with 17p deletion
Dosage
- week 1: 20 mg PO QD
- week 2: 50 mg PO QD
- week 3: 100 mg PO QD
- week 4: 200 mg PO QD
- week 5: 400 mg PO QD (recommended daily dose of 400 mg)
do not chew, crush, or break tablets[4]
Tablets: 10 mg, 50 mg, 100 mg.[5]
Adverse effects
- Serious adverse reactions were reported in 44% of patients
- pneumonia
- febrile neutropenia, pyrexia
- autoimmune hemolytic anemia
- tumor lysis syndrome
- aggressive hydration plus allopurinol or rasburisase to to prevent tumor lysis syndrome[4]
- diarrhea, nausea
- upper respiratory tract infection
- thrombocytopenia
- fatigue
- fetal injury in pregnant women
Drug interactions
- CYP3A inhibitors
- do not use during induction phase
- for maintenance phase, reduce dose of venetoclax by at least 75% when used concomitantly with strong CYP3A inhibitors
- avoid grapefruit
- avoid coadministration with narrow therapeutic window P-glycoprotein substrates (digoxin, everolimus, sirolimus)
- monitor INR closely in patients taking warfarin
- live attenuated vaccine contraindicated
Mechanism of action
- BCL-2 selective inhibitor
More general terms
References
- ↑ Venclexta https://www.venclexta.com/hcp.html
- ↑ FDA News Release. April 11, 2016 FDA approves new drug for chronic lymphocytic leukemia in patients with a specific chromosomal abnormality. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm495253.htm
- ↑ Windle ML FDA Drug Approvals and Changes: May edition. Medscape. May 20, 2016 http://reference.medscape.com/features/slideshow/drug-review/2016/may
- ↑ 4.0 4.1 4.2 VENCLEXTA PRESCRIBING INFORMATION http://www.rxabbvie.com/pdf/venclexta.pdf
- ↑ 5.0 5.1 Medscape: venetoclax (Rx) https://reference.medscape.com/drug/venclexta-venetoclax-1000078